Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Journal of Clinical Oncology ( IF 45.3 ) Pub Date : 2023 , DOI: 10.1200/jco.23.02132
Shannon N Westin ₁ , Kathleen Moore ₂ , Hye Sook Chon ₃ , Jung-Yun Lee ₄ , Jessica Thomes Pepin ₅ , Michael Sundborg ₆ , Ayelet Shai ₇ , Joseph de la Garza ₈ , Shin Nishio ₉ , Michael A Gold ₁₀ , Ke Wang ₁₁ , Kristi McIntyre ₁₂ , Todd D Tillmanns ₁₃ , Stephanie V Blank ₁₄ , Ji-Hong Liu ₁₅ , Michael McCollum ₁₆ , Fernando Contreras Mejia ₁₇ , Tadaaki Nishikawa ₁₈ , Kathryn Pennington ₁₉ , Zoltan Novak ₂₀ , Andreia Cristina De Melo ₂₁ , Jalid Sehouli ₂₂ , Dagmara Klasa-Mazurkiewicz ₂₃ , Christos Papadimitriou ₂₄ , Marta Gil-Martin ₂₅ , Birute Brasiuniene ₂₆ , Conor Donnelly ₂₇ , Paula Michelle Del Rosario ₂₈ , Xiaochun Liu ₂₉ , Els Van Nieuwenhuysen ₃₀ ,

Affiliation

University of Texas MD Anderson Cancer Center, Houston, TX.
Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma, OK.
H.Lee Moffitt Cancer Center, Tampa, FL.
Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Minnesota Oncology, Minneapolis, MN.
FirstHealth Moore Regional Hospital, Pinehurst, NC.
RAMBAM Health Care Campus, Haifa, and Israeli Society of Gynecologic Oncology (ISGO), Israel.
Texas Oncology-San Antonio Medical Center, San Antonio, TX.
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Oklahoma Cancer Specialists and Research Institute, Tulsa, OK.
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Texas Health Presbyterian Hospital, Dallas, TX.
West Cancer Center Research Institute & University of Tennessee Health Science Center, Memphis, TN.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, and GOG Foundation (GOG-F), USA.
Sun Yat-sen University Cancer Center, Guangzhou, China.
Virginia Oncology Associates, Brock Cancer Center, Norfolk, VA, and GOG Foundation (GOG-F), USA.
National Cancer Institute of Colombia, Bogotá, Colombia.
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Fred Hutchinson Cancer Center, University of Washington Medical Center, Seattle, WA.
National Institute of Oncology, Budapest, and Central and Eastern European Gynecologic Oncology Group (CEEGOG), Hungary.
Clinical Research and Technological Development Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
Charité-Department of Gynecology with Center of Oncological Surgery, Universitätsmedizin Berlin, Berlin, and North Eastern German Society of Gynecological Oncology (NOGGO), Germany.
Department of Obstetrics and Gynecology, Gynecological Oncology and Gynecological Endocrinology, Medical University of Gdańsk, Gdańsk, and Polish Gynecologic Oncology Group (PGOG), Poland.
Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, and Hellenic Cooperative Oncology Group (HeCOG), Greece.
Medical Oncology Department, Catalan Institute of Oncology-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, Barcelona, and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Spain.
Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, Vilnius, and Nordic Society of Gynaecological Oncology (NSGO), Lithuania.
Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.
Oncology R&D, Global Medicines Development, AstraZeneca, Cambridge, United Kingdom.
Oncology R&D, Late-stage Development, AstraZeneca, Gaithersburg, MD.
University Hospital Leuven, Leuven, and Luxembourg Gynaecological Oncology Group (BGOG), Belgium.